phenytoin	carbamazepine	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	2002	D010672	2002
phenytoin	carbamazepine	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	2002	D010672	2002
phenytoin	Zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	39998	D010672	C022189
phenytoin	Zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	39998	D010672	C022189
phenytoin	Zonisamide	1	2	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		8183	39998	D010672	C022189
phenytoin	Zonisamide	1	2	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		8183	39998	D010672	C022189
phenytoin	Zonisamide	1	3	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		8183	39998	D010672	C022189
phenytoin	Zonisamide	1	3	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		8183	39998	D010672	C022189
phenytoin	valproate	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	40254	D010672	D014635
phenytoin	valproate	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		8183	40254	D010672	D014635
carbamazepine	Zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		2002	39998	2002	C022189
carbamazepine	Zonisamide	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		2002	39998	2002	C022189
carbamazepine	Zonisamide	1	2	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		2002	39998	2002	C022189
carbamazepine	Zonisamide	1	2	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		2002	39998	2002	C022189
carbamazepine	Zonisamide	1	3	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		2002	39998	2002	C022189
carbamazepine	Zonisamide	1	3	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		2002	39998	2002	C022189
carbamazepine	valproate	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		2002	40254	2002	D014635
carbamazepine	valproate	1	1	false	none	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		2002	40254	2002	D014635
Zonisamide	valproate	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		39998	40254	C022189	D014635
Zonisamide	valproate	1	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  		39998	40254	C022189	D014635
Zonisamide	valproate	2	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		39998	40254	C022189	D014635
Zonisamide	valproate	2	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  		39998	40254	C022189	D014635
Zonisamide	valproate	3	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		39998	40254	C022189	D014635
Zonisamide	valproate	3	1	true	negative	Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials.  Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro.  Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.  		39998	40254	C022189	D014635
